Phesi collaborates with Alfasigma on clinical development

Phesi, provider of AI-based clinical development analytics products and solutions, is showcasing its data-driven clinical development approach at SCOPE Virtual Summit for Clinical Operations Executives 2021, in a case study session with international pharmaceutical company, Alfasigma.

Phesi and Alfasigma are currently working together to maximise the value of priority medical assets, explore the use of synthetic data, and apply advanced analytics to protocol design and investigator site selection.

To support protocol design, performance-based investigator selection, and patient enrollment in clinical trials, Phesi provides clients with its integrated analytics platform, featuring ClinSite, and professional services.

Phesi enables biopharmaceutical companies to examine details on their indications, competition, investigator sites, and patients they want to target. This approach minimizes protocol amendments in clinical trials and maximises patient enrolment, reducing both site and patient burden. Phesi also works with sponsors to determine the feasibility of replacing or supplementing a comparator or placebo arm with a synthetic arm in certain use cases.

“For more than a decade, Phesi has been applying data to solve problems – helping clients to optimise clinical development and become data-driven organisations. As more companies move through their digital transformation journeys, we can help them to better identify and find the right patients, and explore ways they can optimize program design. This includes the use of synthetic trial arms in clinical studies. We are excited to demonstrate our work at SCOPE alongside Alfasigma,” commented Dr Gen Li, President and Founder, Phesi.

“We can quantify data points that make protocol design and enrollment significantly more successful, and thus dramatically reduce costs. Data and analytics play a crucial role in designing and delivering urgent medicines for acute and chronic disease around the world, and we’re looking forward to helping more companies understand the value of this approach,” Dr Li concluded.



Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free